OWC Pharmaceutical Research Corp (OWCP)

[cjstocksup]

OWCP Best OWCP DD post IMO, please read the link below it has everything I only posted atrial below:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125723556 on growth and value of OWCP
OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!

OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.

Big Money to be made here.

Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021
Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024
Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023
Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion
Source links below.


Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.

Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has started the final phase for testing the efficacy of its own developed topical crème compound for the treatment of psoriasis and related skin conditions.

Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.